Advances towards the design and development of personalized non-small-cell lung cancer drug therapy
出版年份 2013 全文链接
标题
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy
作者
关键词
-
出版物
Expert Opinion on Drug Discovery
Volume 8, Issue 11, Pages 1381-1397
出版商
Informa Healthcare
发表日期
2013-10-03
DOI
10.1517/17460441.2013.843523
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.
- (2017) D. R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in Targeting Signal Transduction Pathways.
- (2015) James Andrew McCubrey et al. Oncotarget
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance
- (2015) James Andrew McCubrey et al. Oncotarget
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology
- (2013) C. Ferte et al. CLINICAL CANCER RESEARCH
- Targeting c-MET in the battle against advanced nonsmall-cell lung cancer
- (2013) Lorenza Landi et al. CURRENT OPINION IN ONCOLOGY
- PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine
- (2013) Sara Pilotto et al. EXPERT OPINION ON PHARMACOTHERAPY
- Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer
- (2013) Scott A. Laurie et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2013) Gerold Bepler et al. JOURNAL OF CLINICAL ONCOLOGY
- Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
- (2013) Tony Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
- (2013) N. Tan et al. MOLECULAR CANCER THERAPEUTICS
- Non-small cell lung cancer, locally advanced
- (2012) S. I. Ou et al. ANNALS OF ONCOLOGY
- MEK genomics in development and disease
- (2012) J. L. Bromberg-White et al. Briefings in Functional Genomics
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
- (2012) S. V. Holt et al. CANCER RESEARCH
- MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
- (2012) Sidong Huang et al. CELL
- The Genetic Basis for Cancer Treatment Decisions
- (2012) Janet E. Dancey et al. CELL
- Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
- (2012) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
- (2012) L. Gandhi et al. CLINICAL CANCER RESEARCH
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer
- (2012) Giorgio V. Scagliotti et al. Clinical Lung Cancer
- Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
- (2012) S. A. Kono et al. CURRENT CANCER DRUG TARGETS
- Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
- (2012) Rachana Patel et al. CURRENT PHARMACEUTICAL DESIGN
- Crizotinib in the treatment of non-small-cell lung cancer
- (2012) Patrick M Forde et al. EXPERT OPINION ON PHARMACOTHERAPY
- Anaplastic lymphoma kinase as a therapeutic target
- (2012) Anna Kruczynski et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
- (2012) Asuka Nakata et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
- (2012) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping
- (2012) Angela Zupa et al. Journal of Thoracic Oncology
- Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study
- (2012) Thanyanan Reungwetwattana et al. Journal of Thoracic Oncology
- Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
- (2012) Vassiliki Papadimitrakopoulou Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- KIF5B-RET fusions in lung adenocarcinoma
- (2012) Takashi Kohno et al. NATURE MEDICINE
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters
- (2012) Yong He et al. PLoS One
- Adaptive trial designs: a review of barriers and opportunities
- (2012) John A Kairalla et al. Trials
- Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis
- (2011) E. Bria et al. ANNALS OF ONCOLOGY
- Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC)
- (2011) Meiju Ji et al. BMC CANCER
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy
- (2011) Cheng-Xiong Xu et al. CANCER BIOLOGY & THERAPY
- Targeting phosphoinositide 3-kinase signalling in lung cancer
- (2011) Anna Wojtalla et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeted agents: How to select the winners in preclinical and early clinical studies?
- (2011) Rachel Goodwin et al. EUROPEAN JOURNAL OF CANCER
- Mutual exclusivity analysis identifies oncogenic network modules
- (2011) G. Ciriello et al. GENOME RESEARCH
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- (2011) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protein Pathway Activation Mapping of Brain Metastasis from Lung and Breast Cancers Reveals Organ Type Specific Drug Target Activation
- (2011) Giuseppina Improta et al. JOURNAL OF PROTEOME RESEARCH
- Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model
- (2011) Johan Vansteenkiste et al. Journal of Thoracic Oncology
- MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
- (2011) Junko Tanizaki et al. Journal of Thoracic Oncology
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
- (2011) M Konopleva et al. LEUKEMIA
- Harnessing synthetic lethal interactions in anticancer drug discovery
- (2011) Denise A. Chan et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) G. D'Addario et al. ANNALS OF ONCOLOGY
- Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM
- (2010) Charles J. Vaske et al. BIOINFORMATICS
- A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer
- (2010) Grace K. Dy et al. CANCER
- Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
- (2010) Suresh S. Ramalingam et al. CANCER
- Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung
- (2010) Donatella Malanga et al. CELL CYCLE
- Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
- (2010) A. Tarhini et al. CLINICAL CANCER RESEARCH
- Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
- (2010) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers
- (2010) Shin Yup Lee et al. Journal of Thoracic Oncology
- Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
- (2010) Katharine A. Price et al. Journal of Thoracic Oncology
- Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence
- (2010) Meera Nanjundan et al. Journal of Thoracic Oncology
- A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
- (2010) John D. Hainsworth et al. Journal of Thoracic Oncology
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Reverse phase protein microarrays advance to use in clinical trials
- (2010) Claudius Mueller et al. Molecular Oncology
- Translating cancer research into targeted therapeutics
- (2010) J. S. de Bono et al. NATURE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Therapeutic Target for Smoking-Associated Lung Cancer
- (2010) N. C. Turner et al. Science Translational Medicine
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
- (2009) J.-C. Soria et al. ANNALS OF ONCOLOGY
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Antibody-based proteomics
- (2009) Hans Voshol et al. FEBS Journal
- Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non–Small-Cell Lung Cancer
- (2009) George R. Blumenschein et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Methodological aspects of lung cancer clinical trials in the era of targeted agents
- (2009) Massimo Di Maio et al. LUNG CANCER
- NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
- (2009) T.-J. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer
- (2009) J Mullenders et al. ONCOGENE
- Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
- (2008) C. A. Pratilas et al. CANCER RESEARCH
- Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma
- (2008) J. L. Marks et al. CANCER RESEARCH
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
- (2008) H. Yamamoto et al. CANCER RESEARCH
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
- (2008) Mark S. Cragg et al. JOURNAL OF CLINICAL INVESTIGATION
- First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
- (2008) Andrea Molckovsky et al. Journal of Hematology & Oncology
- Multiplexed Cell Signaling Analysis of Human Breast Cancer Applications for Personalized Therapy
- (2008) Julia D. Wulfkuhle et al. JOURNAL OF PROTEOME RESEARCH
- Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer
- (2008) Amy J. VanMeter et al. MOLECULAR & CELLULAR PROTEOMICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- AKT1 E17K in human solid tumours
- (2008) F E Bleeker et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now